Stock LCTX LINEAGE CELL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Lineage Cell Therapeutics, Inc.

Consensus Lineage Cell Therapeutics, Inc.

Equities

LCTX

US53566P1093

Market Closed - Nyse
Other stock markets
 04:00:00 2023-12-06 pm EST 		Intraday chart for Lineage Cell Therapeutics, Inc. 5-day change 1st Jan Change
1.02 USD +2.00% +0.99% -12.82%
Nov. 09 Transcript : Lineage Cell Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023 CI
Nov. 09 Lineage Cell Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Evolution of the average Target Price on Lineage Cell Therapeutics, Inc.

Price target over the last 5 years

History : Analyst Recommendations

6a40db51ea35ef432f6c37.teIJTQYZr667l31B3_zajMQ1ERsRpPwIaGCQHWxrJcw.x6ZIeGdD3OH_oDgxjLKF3I9sZ1p4y6x-DzP2cx87SP-FlVoORUjMl4_kMA~f6e82d3ea2d80fa540e593b704e2253a

Analyst Recommendations on Lineage Cell Therapeutics, Inc.

Baird Starts Lineage Cell Therapeutics at Outperform With $5 Price Target MT
B. Riley Initiates Lineage Cell Therapeutics at Buy with $4 Price Target, Says Platform, Pipeline Currently Undervalued MT
LINEAGE CELL THERAPEUTICS : Noble Capital Initiates Coverage on Lineage Cell Therapeutics With Outperform Rating, $8 Price Target MT
LINEAGE CELL THERAPEUTICS : Chardan Suspends Coverage on Lineage Cell Therapeutics at Buy Rating With $4 Price Target MT
LINEAGE CELL THERAPEUTICS : Cantor Fitzgerald Starts Lineage Cell Therapeutics at Overweight With $6 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.02USD
Average target price
5.4USD
Spread / Average Target
+429.41%
High Price Target
7USD
Spread / Highest target
+586.27%
Low Price Target
4USD
Spread / Lowest Target
+292.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lineage Cell Therapeutics, Inc.

Baird
B. Riley
Noble Capital
Chardan
Cantor Fitzgerald

Ratings for Lineage Cell Therapeutics, Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock
  2. Equities
  3. Stock Lineage Cell Therapeutics, Inc. - Nyse
  4. Consensus Lineage Cell Therapeutics, Inc.
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer